The Office of Research and the School of Medicine had planned to introduce their Oct. 30 speaking guest as a professor and the founder and director of the Innovative Genomics Institute at UC Berkeley, and a CRISPR pioneer.

Since being booked for the Distinguished Speaker Series in Research and Innovation, however, Jennifer Doudna has added a new title: Nobel laureate.

She and Emmanuelle Charpentier, director of the Max Planck Institute for Infection Biology, won the Nobel Prize in chemistry Oct. 7 for their co-development of CRISPR-Cas9, a genome editing tool that has revolutionized biomedicine and agriculture.

Whats CRISPR? Jennifer Doudna explains in a Radiolab podcast.

Doudna became the first woman on the UC Berkeley faculty to win a Nobel, and she and Charpentier are the first women to share a Nobel in the sciences.

Doudnas topic for her UC Davis talk is CRISPR and Coronavirus.

UC Davis Healths Ralph Green, distinguished professor in the Department of Pathology and Laboratory Medicine, and medical director of UC Davis Diagnostics, recently collaborated with Doudna and others on a project to set up COVID-19 testing for UC Berkeley and the surrounding community and Green is helping with a similar project at UC Davis.

I had the good fortune to get to know Jennifer Doudna through my interaction with her group when they turned their skills and knowledge to setting up, at remarkable speed, a pop-up, PCR-based test for SARS-CoV-2 during the early days of the COVID-19 pandemic when the country was scrambling to meet the need for more testing, Green said.

I have to say that it has been a singular pleasure and privilege for me to interact with Jennifer Doudna and her colleagues.

CRISPR-Cas9 genetic engineering technology enables scientists to change or remove genes quickly and with great precision. Labs worldwide have redirected their research programs to incorporate this new tool, creating a CRISPR revolution with huge implications across biology and medicine.

Doudna is a leader in public discussion of the ethical implications of genome editing for human biology and societies. She advocates for thoughtful approaches to the development of policies around the use of CRISPR-Cas9.

Follow Dateline UC Davis on Twitter.

See the article here:
'CRISPR and Coronavirus': Hear From Nobel Winner Jennifer Doudna - UC Davis

Recommendation and review posted by Bethany Smith

From the beginning, Pfizer CEO Albert Bourla eschewed government funding for his Covid-19 vaccine work with BioNTech, willing to take all the $2 billion-plus risk of a lightning-fast development campaign in exchange for all the rewards that could fall its way with success. And now that the pharma giant has seized a solid lead in the race to the market, those rewards loom large.

SVB Leerinks Geoff Porges has been running the numbers on Pfizers vaccine, the mRNA BNT162b2 program that the German biotech partnered on. And he sees a $3.5 billion peak in windfall revenue next year alone. Even after the pandemic is brought to heel, though, Porges sees a continuing blockbuster role for this vaccine as people around the world look to guard against a new, thoroughly endemic virus that will pose a permanent threat.

Unlock this story instantly and join 92,200+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Read the rest here:
UPDATED: CRISPR Therapeutics gets a snapshot of off-the-shelf CAR-T success in B-cell malignancies marred by the death of a patient - Endpoints News

Recommendation and review posted by Bethany Smith

Its been a good year for Intellia: One of its founders, Jennifer Doudna, Ph.D., nabbed the Nobel Prize in Chemistry for her CRISPR research.

Now, the biotech she helped build is putting that to work, saying it now plans the worlds first clinical trial for asingle-course therapy that potentially halts and reverses a condition known as hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN).

This genetic disorder occurs when a person is born with a specific DNA mutation in the TTR gene, which causes the liver to produce a protein called transthyretin (TTR) in a misfolded form and build up in the body.

How to Streamline Your Clinical Research Organization's Processes End to End

Learn how implementing one platform leads to data consistency and ultimately facilitate faster clinical trials while reducing overall trial costs, leave behind spreadsheets and home-grown tools for a predictable trial and the ability to forecast unit delivery resulting in the optics you need to ensure a successful trial, and hear experts share industry trends of what is affecting the Clinical Research Organization industry today.

hATTR can manifest as polyneuropathy (hATTR-PN), which can lead to nerve damage, or cardiomyopathy (hATTR-CM), which involves heart muscle disease that can lead to heart failure.

This disorder has seen a lot of interest in recent years, with an RNAi approach from Alnylam seeing an approval for Onpattro a few years back, specifically for hATTR in adults with damage to peripheral nerves.

Ionis Pharmaceuticals and its rival RNAi drug Tegsedi also saw an approval in 2018 for a similar indication.

They both battle with Pfizers older med tafamidis, which has been approved in Europe for years in polyneuropathy, and the fight could spread to the U.S. soon.

The drug, now marketed as Vyndaqel and Vyndamax, snatched up an FDA nod last May to treat both hereditary and wild-type ATTR patients with a heart condition called cardiomyopathy.

While coming into an increasingly crowed R&D area, Intellia is looking for a next-gen approach, and has been given the go-ahead by regulators ion the U.K, to start a phase 1 this year.

The idea is for Intellias candidate NTLA-2001, which is also partnered with Regeneron, to go beyond its rivals and be the first curative treatment for ATTR.

By applying the companys in vivo liver knockout technology, NTLA-2001 allows for the possibility of lifelong transthyretin (TTR) protein reduction after a single course of treatment. If this works, this could in essence cure patients of the their disease.

The 38-patient is set to start by years end.

Starting our global NTLA-2001 Phase 1 trial for ATTR patients is a major milestone in Intellias mission to develop medicines to cure severe and life-threatening diseases, said Intellias president and chief John Leonard, M.D.

Our trial is the first step toward demonstrating that our therapeutic approach could have a permanent effect, potentially halting and reversing all forms of ATTR. Once we have established safety and the optimal dose, our goal is to expand this study and rapidly move to pivotal studies, in which we aim to enroll both polyneuropathy and cardiomyopathy patients."

Continue reading here:
Intellia to kick-start first single-course 'curative' CRISPR shot, as it hopes to beat rivals Alnylam, Ionis and Pfizer - FierceBiotech

Recommendation and review posted by Bethany Smith

In a study published [September 21] in theNature Biomedical Engineeringjournal, the researchers said they usedCRISPRCas9 and a combination of other genetic technologies to inactivate porcine endogenous retroviruses (PERVs), a group of viruses that could be dangerous to humans, while also enhancing the pigs immunological and blood-coagulation compatibility with humans, which could reduce the risk of rejection by organ recipients.

The engineered pigs exhibited normal physiology, fertility and transmission of the edited genes to their offspring, according to the paper.

Transplants from pigs have long been investigated as a solution to the global shortage of human organs for patients with organ failure, for reasons such as the size of their organs similar enough to those of humans and their relatively short maturity period of about six months.

The risks of organ rejection due to the biological incompatibility of pig organs with human bodies and of transmitting PERVs have limited the clinical applicability of such transplants, but advancements in gene-editing technology have given researchers new hope.

George Church, one of the authors from Harvard Medical School and a co-founder of Hangzhou-based Qihan Bio, was quoted by Chinese news agency Xinhua as saying that if the technology used can be further verified in future research, it could help alleviate the global shortage of human organs to a large extent.

Read the original post

Read more here:
CRISPR has brought pig-to-human organ transplants to the cusp of reality - Genetic Literacy Project

Recommendation and review posted by Bethany Smith

The global CRISPR Cas9 Industry Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global CRISPR Cas9 Industry market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global CRISPR Cas9 Industry market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global CRISPR Cas9 Industry market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global CRISPR Cas9 Industry market.

The research report on CRISPR Cas9 Industry market elaborates on the major trends defining the industry growth with regards to the regional terrain and competitive scenario. The document also lists out the limitations & challenges faced by industry participants alongside information such as growth opportunities. Apart from this, the report contains information regarding the impact of COVID-19 pandemic on the overall market outlook.

Key insights from COVID-19 impact analysis:

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/228075

An overview of regional landscape:

Additional information from the CRISPR Cas9 Industry market report:

Table of Contents

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/228075

Visit link:
CRISPR Cas9 Industry Market Overview, Environmental Analysis and Forecast to 2025 - Express Journal

Recommendation and review posted by Bethany Smith

A researcher observes the process of genetic scissors in a laboratory in Berlin (Germany). (GREGOR FISCHER / DPA)

The genetic scissors, called Crispr-Case 9 discovered almost ten years ago, are actually genetic code scissors. They make it possible to separate two strands of DNA and replace or delete a gene. When American and French scientists Jennifer Doudna and Emmanuelle Charpentier made this discovery, it paved the way for much research. Today, American, European and Australian scientists are meeting in videoconference to take stock of their progress.

For example, Crispr is making great progress in research into gene therapy. Today, this technique makes it possible to treat people with Duchenne muscular dystrophy, one of the genetic diseases often mentioned during the Telethon. Inserm was also able to reactivate a gene to fight against sickle cell anemia: a blood disease linked again to a genetic problem. Moreover, the company eGenesis works on pigs free of viruses dangerous to humans. The animals would then become perfect organ donors for patients awaiting transplants of the heart, pancreas, etc.

The Crispr technique has developed in many laboratories around the world and two years ago a Chinese researcher, He Jiankui, caused a scandal after announcing that he had used it to create, through in vitro fertilization, two GMO babies resistant to HIV whose father was a carrier. According to a survey, in the MIT Technology Review, the researcher forced the hand of parents who saw in this genetic manipulation the only way to have children without risk. In addition, today it is not known how babies are doing and what other genetic consequences the use of Crispr has had on them. The researcher is still under house arrest in China.

Emmanuelle Charpentier in an interview on point obviously criticizes the failure to respect ethical criteria for the use of its scissors applied to research for humans. On the other hand, she does not share the doubts of peasant and environmental associations on plants modified by Crispr-Cas 9 and considered as GMOs in Europe. For her, her innovation makes it possible to boost a plant gene, to reproduce in an accelerated manner what can happen in nature. Its not like creating mutant plants with a gene that comes from other species.

Applied to theAgriculture, Crispr-Cas 9 makes it possible to create allergen-free peanuts, gluten-free wheat, more drought-resistant rice, but also to remove the horns of cows or to herd only males. Crispr-Cas 9 therefore asks even more to meditate on Rabelais sentence: Science without consciousness is nothing but the ruin of the soul.

See the original post:
Advances and concerns raised by Crispr-Cas 9, the genetic scissors - Pledge Times

Recommendation and review posted by Bethany Smith

Chemistry Nobel Prize award recipients Jennifer A. Doudna and Emmanuelle Charpentier have joined the ranks of Marie Curie, Frances Arnold, Ada E. Yonath and Dorothy Crowfoot Hodgkin.J.L. Cereijido/EPA

THE Royal Swedish Academy of Sciences yesterday awarded the 2020 Nobel Prize in Chemistry to Emmanuelle Charpentier and Jennifer Doudna for their work on CRISPR, a method of genome editing.

A genome is the full set of genetic instructions that determine how an organism will develop. Using CRISPR, researchers can cut up DNA in an organisms genome and edit its sequence.

CRISPR technology is a powerhouse for basic research and is also changing the world we live in. There are thousands of research papers published every year on its various applications.

These include accelerating research into cancers, mental illness, potential animal to human organ transplants, better food production, eliminating malaria-carrying mosquitoes and saving animals from disease.

Charpentier is the director at the Max Planck Institute for Infection Biology in Berlin, Germany and Doudna is a professor at the University of California, Berkeley. Both played a crucial role in demonstrating how CRISPR could be used to target DNA sequences of interest.

Read more:Why more women dont win science Nobels

CRISPR technology is adapted from a system that is naturally present in bacteria and other unicellular organisms known as archaea.

This natural system gives bacteria a form of acquired immunity. It protects them from foreign genetic elements (such as invading viruses) and lets them remember these in case they reappear.

Like most advances in modern science, the discovery of CRISPR and its emergence as a key genome editing method involved efforts by many researchers, over several decades.

In 1987, Japanese molecular biologist Yoshizumi Ishino and his colleagues were the first to notice, in E. coli bacteria, unusual clusters of repeated DNA sequences interrupted by short sequences.

Spanish molecular biologist Francisco Mojica and colleagues later showed similar structures were present in other organisms and proposed to call them CRISPR: Clustered Regularly Interspaced Short Palindromic Repeats.

In 2005, Mojica and other groups reported the short sequences (or spacers) interrupting the repeats were derived from other DNA belonging to viruses.

Evolutionary biologists Kira Makarova, Eugene Koonin and colleagues eventually proposed CRISPR and the associated Cas9 genes were acting as the immune mechanism. This was experimentally confirmed in 2007 by Rodolphe Barrangou and colleagues.

The CRISPR-associated genes, Cas9, encode a protein that cuts DNA. This is the active part of the defence against viruses, as it destroys the invading DNA.

In 2012, Charpentier and Doudna showed the spacers acted as markers that guided where Cas9 would make a cut in the DNA. They also showed an artificial Cas9 system could be programmed to target any DNA sequence in a lab setting.

This was a groundbreaking discovery which opened the door for CRISPRs wider applications in research.

In 2013, for the first time, groups led by American biochemist Feng Zhang and geneticist George Church reported genome editing in human cell cultures using CRISPR-Cas9. It has since been used in countless organisms from yeast to cows, plants and corals.

Today, CRISPR is the preferred gene-editing tool for thousands of researchers.

Humans have altered the genomes of species for thousands of years. Initially, this was through approaches such as selective breeding.

However, genetic engineering the direct manipulation of DNA by humans outside of breeding and mutations has only existed since the 1970s.

CRISPR-based systems fundamentally changed this field, as they allow for genomes to be edited in living organisms cheaply, with ease and with extreme precision.

CRISPR is currently making a huge impact in health. There are clinical trials on its use for blood disorders such as sickle cell disease or beta-thalassemia, for the treatment of the most common cause of inherited childhood blindness (Leber congenital amaurosis) and for cancer immunotherapy.

CRISPR also has great potential in food production. It can be used to improve crop quality, yield, disease resistance and herbicide resistance.

Used on livestock, it can lead to better disease resistance, increased animal welfare and improved productive traits that is, animals producing more meat, milk or high-quality wool.

A number of challenges to the technology remain, however. Some are technical, such as the risk of off-target modifications (which happen when Cas9 cuts at unintended locations in the genome).

Other problems are societal. CRISPR was famously used in one of the most controversial experiments of recent years.

Read more:Why we need a global citizens assembly on gene editing

Chinese biophysicist He Jiankui unsuccessfully attempted to use the technology to modify human embryos and make them resistant to HIV (human immunodeficiency virus). This led to the birth of twins Lulu and Nana.

We need a broad and inclusive discussion on the regulation of such technologies especially given their vast applications and potential.

To quote CRISPR researcher Fyodor Urnov, Charpentier and Doudnas work really has changed everything.

Dimitri Perrin, Senior Lecturer, Queensland University of Technology

This article is republished from The Conversation under a Creative Commons license. Read the original article.

See the original post:
What is CRISPR, the gene editing technology that won the Chemistry Nobel prize? - Grain Central

Recommendation and review posted by Bethany Smith

As we know, COVID-19 is causing large scale loss of life and severe human suffering. With the pandemic spreading across the globe, researchers are racing against the clock to develop diagnostic tools, vaccines and treatments. Recently, WHO has launched a Solidarity clinical trial to assess relative effectiveness of four potential drugs against COVID-19. Further, there are close to 40 clinical trials of vaccines are ongoing, however, as per experts, it may take more than a year to develop a vaccine.

In order to enhance COVID-19 drug discovery and develop rapid testing kits, various academic institutes, non-profit institutes, scientific pioneers and biopharmaceutical companies have also been leveraging benefits of CRISPR technology.

For more Insights Click under

CRISPR Can be a Solution to Address the COVID-19 Pandemic

The CRISPR / Cas9 system has revolutionized the field of genetic engineering. It enables researchers to alter the genomes of a range of organisms with relative ease. Currently, it has emerged as a promising tool that is used extensively for editing genomes and for the development of novel treatment options. CRISPR is popularly known as search engine for biology, as it has emerged as a location finder, rather than site specific cleavage tool. The figure below highlights the key potential areas and benefits of CRISPR in order to fight against novel coronavirus.

Rapid and Economical Diagnostic Tests

Presently, COVID-19 testing capacity is limited by a number of factors, such as requirements for complex procedures, need for laboratory instrumentation, and dependence on limited supplies. Therefore, there is an urgent need for rapid detection kits. CRISPR has been explored by scientists for diagnosis of infectious diseases. The underlying mechanism involves binding of guide RNA with a protein of Cas family which cuts the target and shreds the nearby RNA or DNA. When CRISPR hits a target, the reporter molecule releases a fluorescent signal. This is further analysed by paper tests dipped into a patient sample, such as blood, urine, or saliva, which further shows up as a line on the testing strip. Researchers have been utilizing CRISPR-based tools and technologies to detect RNA of virus in patient samples. Sherlock Biosciences has already made history, as it received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its Sherlock CRISPR SARS-CoV-2 kit for the detection of the virus that causes COVID-19. The kit is designed for use in laboratories and can provide results within an hour. The company claims that more than 1 million tests can be performed within a week.

Enhancing Drug Discovery

CRISPR technology aids in the study of interaction of virus with human cells. This enables the generation of appropriate cell models for faster discovery of new potential treatment options, or identification of an existing drug combination that may provide a treatment solution. For instance, researchers are exploring molecular mechanisms of the novel virus by utilizing CRISPR technology, which can ultimately assist in identifying potential drug combinations.

CRISPR-based COVID-19 Therapy

Researchers at Stanford University have been working on the development of a gene targeting anti-viral agent against COVID-19, using PAC-MAN technology. The technology has been modified to be used against the deadly virus. It consists of a virus-killing enzyme, such as Cas13 and a guide RNA, which commands Cas13 to destroy specific nucleotide sequences in the coronaviruss genome. Based on several studies, it has been revealed that PAC-MAN has the ability to neutralize the coronavirus and stop it from replicating inside cells. Based on information available, work is currently ongoing, and researchers are finding a solution to deliver this technology to lung cells. Multiple delivery methods are currently under evaluation.

A lot of companies are currently active in providing CRISPR-based genome engineering services. To get a detailed information on the key players, recent developments, and the likely market evolution.

For more Insights Click under

CRISPR Can be a Solution to Address the COVID-19 Pandemic

You may also be interested in the following titles:

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If youd like help with your growing business needs, get in touch at [emailprotected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[emailprotected]

See the rest here:
CRISPR Can be a Solution to Address the COVID-19 Pandemic | Roots Analysis - Eurowire

Recommendation and review posted by Bethany Smith

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Crispr Therapeutics AG (CRSP). The companys shares closed last Wednesday at $94.30.

According to TipRanks.com, Prasad is a 5-star analyst with an average return of 13.4% and a 53.9% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Rocket Pharmaceuticals.

Currently, the analyst consensus on Crispr Therapeutics AG is a Strong Buy with an average price target of $95.88, implying a 5.1% upside from current levels. In a report released today, Needham also assigned a Buy rating to the stock with a $105.00 price target.

See todays analyst top recommended stocks >>

The company has a one-year high of $111.90 and a one-year low of $32.30. Currently, Crispr Therapeutics AG has an average volume of 870.1K.

Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

View post:
William Blair Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP) - Smarter Analyst

Recommendation and review posted by Bethany Smith

CRISPR And CRISPR-Associated (Cas) Genes Market report would come handy to understand the competitors in the market and give an insight into sales, volumes, revenues in the CRISPR And CRISPR-Associated (Cas) Genes Industry & will also assists in making strategic decisions. The report also helps to decide corporate product & marketing strategies. It reduces the risks involved in making decisions as well as strategies for companies and individuals interested in the CRISPR And CRISPR-Associated (Cas) Genes industry. Both established and new players in CRISPR And CRISPR-Associated (Cas) Genes industries can use the report to understand the CRISPR And CRISPR-Associated (Cas) Genes market.

In Global Market, the Following Companies Are Covered:

Get a Sample Copy of the Report @ https://www.360marketupdates.com/enquiry/request-sample/14841056

Analysis of the Market:

Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of spacer DNA from previous exposures to a bacteriophage virus or plasmid.

The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages, and provides a form of acquired immunity. CRISPR associated proteins (Cas) use the CRISPR spacers to recognize and cut these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms. CRISPRs are found in approximately 40% of sequenced bacterial genomes and 90% of sequenced archaea.

CRISPR And CRISPR-Associated (Cas) Genes industry is relatively concentrated, manufacturers are mostly in the Europe and North America. Among them, North America region accounted for more than 45.70% of the total market of global CRISPR And CRISPR-Associated (Cas) Genes.

The global CRISPR And CRISPR-Associated (Cas) Genes market is valued at 713.8 million USD in 2020 is expected to reach 7696.7 million USD by the end of 2026, growing at a CAGR of 40.0% during 2021-2026.

This report focuses on CRISPR And CRISPR-Associated (Cas) Genes volume and value at the global level, regional level and company level. From a global perspective, this report represents overall CRISPR And CRISPR-Associated (Cas) Genes market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan et

CRISPR And CRISPR-Associated (Cas) Genes Market Breakdown by Types:

CRISPR And CRISPR-Associated (Cas) Genes Market Breakdown by Application:

Critical highlights covered in the Global CRISPR And CRISPR-Associated (Cas) Genes market include:

The information available in the CRISPR And CRISPR-Associated (Cas) Genes Market report is segmented for proper understanding. The Table of contents contains Market outline, Market characteristics, Market segmentation analysis, Market sizing, customer landscape & Regional landscape. For further improving the understand ability various exhibits (Tabular Data & Pie Charts) has also been used in the CRISPR And CRISPR-Associated (Cas) Genes Market report.

Get a Sample Copy of the Report @ https://www.360marketupdates.com/enquiry/request-sample/14841056

Reasons for Buy CRISPR And CRISPR-Associated (Cas) Genes Market Report:

In the end, CRISPR And CRISPR-Associated (Cas) Genes Industry report provides the main region, market conditions with the product price,profit, capacity, production, supply, demand and market growth rateand forecast etc. This report also Present newproject SWOT analysis,investment feasibility analysis, andinvestment return analysis.

Contact Us:

Name: Mr. Ajay More

Email: [emailprotected]

Organization: 360 Market Updates

Phone: +14242530807 / + 44 20 3239 8187

Global Shortening Market Size in 2020 (New Report): Manufacturers Data, Opportunity, Import Export Scenario, Application, Showing Impressive Growth by 2026

Swimwear and Beachwear Market Size 2020-2026 Research Report by Key Companies, Future Trend, Pipeline Projects, Product, Application, Growth and Regional Forecasts

Trunking System Market Size 2020 : Business Opportunity, SWOT Analysis, Applications, Trends and Forecast to 2026 Research Reportby360marketupdates

Global Acraldehyde Market 2020 Industry Analysis, Size, Share, Trends, Market Demand, Growth, Opportunities and Showing Impressive Growth by 2026

Medical Robotic Systems Market Size 2020-2026 Industry Trends, Size, Segments, Competitors Classification, Growth, Up and Down Stream Industry Analysis and Forecast

Solid of Sodium Methylate Market Size, Growth Opportunities, Emerging Technologies, Trends,Growth, Segments, Landscape and Demandby usingForecast to 2026 Research Reportvia360marketupdates

Go here to read the rest:
CRISPR And CRISPR-Associated (Cas) Genes Market 2020 to Flourish with an Impressive CAGR of XX% in the year 2026, Market Size & Growth with...

Recommendation and review posted by Bethany Smith

Report is a detailed study of the CRISPR and CAS Gene market, which covers all the essential information required by a new market entrant as well as the existing players to gain a deeper understanding of the market. The primary objective of this research report named CRISPR and CAS Gene market is to help making reliable strategic decisions regarding the opportunities in CRISPR and CAS Gene market.

Major Market Players with an in-depth analysis:

Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc.

Request Free Sample Copy of CRISPR and CAS Gene Market Research [emailprotected]:https://www.coherentmarketinsights.com/insight/request-sample/2598

The Global CRISPR and CAS Gene Market segments and Market Data Break Down are illuminated below:

By Product Type:Vector-based CasDNA-free CasGlobal CRISPR and CAS Gene Market, By Application:Genome EngineeringDisease modelsFunctional GenomicsKnockdown/activationOther Applications

The CRISPR and CAS Gene market report offers the current state of the market around the world. The report starts with the market outline and key of the CRISPR and CAS Gene market which assumes a significant job for clients to settle on the business choice. It additionally offers the key focuses to upgrade the development in the CRISPR and CAS Gene market. Some fundamental ideas are likewise secured by reports, for example, item definition, its application, industry esteem chain structure and division which help the client to break down the market without any problem. Also, the report covers different factors, for example, arrangements, efficient and innovative which are affecting the CRISPR and CAS Gene business and market elements.

Download Sample Report of CRISPR and CAS Gene Market Report 2020 (Coronavirus Impact Analysis on CRISPR and CAS Gene Market)

Competitive Analysis has been done to understand overall market which will be helpful to take decisions. Major players involved in the manufacture of CRISPR and CAS Gene product has been completely profiled along with their SWOT. Some of the key players include Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc. It helps in understanding their strategy and activities. Business strategy described for every company helps to get idea about the current trends of company. The industry intelligence study of the CRISPR and CAS Gene market covers the estimation size of the market each in phrases of value (Mn/Bn USD) and volume (tons). Report involves detailed chapter on COVID 19 and its impact on this market. Additionally, it involves changing consumer behavior due to outbreak of COVID 19.

Further, report consists of Porters Five Forces and BCG matrix as well as product life cycle to help you in taking wise decisions. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Regional Analysis for CRISPR and CAS Gene

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample):https://www.coherentmarketinsights.com/insight/request-discount/2598

Chapters Define in TOC (Table of Content) of the Report:

Chapter 1: Market Overview, Drivers, Restraints and Opportunities, Segmentation

Overview

Chapter 2: COVID Impact

Chapter 3: Market Competition by Manufacturers

Chapter 4: Production by Regions

Chapter 5: Consumption by Regions

Chapter 6: Production, By Types, Revenue and Market share by Types

Chapter 7: Consumption, By Applications, Market share (%) and Growth Rate by

Applications

Chapter 8: Complete profiling and analysis of Manufacturers

Chapter 9: Manufacturing cost analysis, Raw materials analysis, Region-wise

Manufacturing expenses

Chapter 10: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 11: Marketing Strategy Analysis, Distributors/Traders

Chapter 12: Market Effect Factors Analysis

Chapter 13: Market Forecast

Chapter 14: CRISPR and CAS Gene Research Findings and Conclusion, Appendix, methodology and data source

DOWNLOAD FREE SAMPLE [emailprotected]:https://www.coherentmarketinsights.com/insight/request-sample/2598

The qualitative contents for geographical analysis will cover market trends in each region and country which includes highlights of the key players operating in the respective region/country, PEST analysis of each region which includes political, economic, social and technological factors influencing the growth of the market. The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2020 to 2027.

About Us:

Coherent Market Insightsis a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts Us: +1-206-701-6702Email: [emailprotected]Web: https://www.coherentmarketinsights.com/

**********Download the Entire Report*************************************************

https://www.coherentmarketinsights.com/market-insight/crispr-and-cas-gene-market-2598

Go here to read the rest:
Covid-19 Impact On CRISPR and CAS Gene Market Study: An Emerging Hint of Opportunity Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC,...

Recommendation and review posted by Bethany Smith

Share this Article

You are free to share this article under the Attribution 4.0 International license.

New generation CRISPR technology could pave the way for therapeutics to treat inherited retina diseases, researchers report.

In this proof-of-concept study, we provide evidence of the clinical potential of base editors for the correction of mutations causing inherited retinal diseases and for restoring visual function, says Krzysztof Palczewski, chair and a professor in the Gavin Herbert Eye Institutes ophthalmology department at the University of California, Irvine School of Medicine. Our results demonstrate the most successful rescue of blindness to date using genome editing.

Inherited retinal diseases (IRDs) are a group of blinding conditions caused by mutations in more than 250 different genes. Previously, there was no avenue available for treating these devastating blinding diseases. Recently, the FDA approved the first gene augmentation therapy for Leber congenital amaurosis (LCA), a common form of IRD which originates during childhood.

As an alternative to gene augmentation therapy, we applied a new generation of CRISPR technology, referred to as base editing as a treatment for inherited retinal diseases, says first author Susie Suh, assistant specialist in the ophthalmology department.

We overcame some of the barriers to the CRISPR-Cas9 system, such as unpredictable off-target mutations and low editing efficiency, by utilizing cytosine and adenine base editors (CBE and ABE). Use of these editors enabled us to correct point mutations in a precise and predictable manner while minimizing unintended mutations that could potentially cause undesirable side effects, says co-first author Elliot Choi, also an assistant specialist in the ophthalmology department.

Using an LCA mouse model harboring a clinically relevant pathogenic mutation in the Rpe65 gene, the researchers successfully demonstrated the therapeutic potential of base editing for the treatment of LCA and by extension other inherited blinding diseases.

Among other results, the base editing treatment restored retinal and visual function in LCA mice to near-normal levels. Base editing was developed at the Broad Institute of MIT and Harvard in the lab of David Liu.

After receiving treatment, the mice in our study could discriminate visual changes in terms of direction, size, contrast, and spatial and temporal frequency, says Palczewski.

These results are extremely encouraging and represent a major advance towards the development of treatments for inherited retinal diseases.

Gene therapy approaches to treating inherited retinal diseases are of special interest given the accessibility of the eye, its immune-privileged status, and the successful clinical trials of RPE65 gene augmentation therapy that led to the first US Food and Drug Administration-approved gene therapy.

Now, as demonstrated in this study, base-editing technology can provide an alternative treatment model of gene augmentation therapy to permanently rescue the function of a key vision-related protein disabled by mutations.

The new paper appears in Nature Biomedical Engineering.

Support for the research came from the National Institutes of Health; the Research to Prevent Blindness Stein Innovation Award; Fight for Sight; the Eye and Tissue Bank Foundation (Finland); the Finnish Cultural Foundation; the Orion Research Foundation; the Helen Hay Whitney Foundation; US Department of Veterans Affairs; and a Research to Prevent Blindness unrestricted grant to the Department of Ophthalmology, University of California, Irvine.

Source: UC Irvine

The rest is here:
Therapy restores vision in mice with retina disease - Futurity: Research News

Recommendation and review posted by Bethany Smith

Here are some events that caught our eye, either because of their nod to current events or their unique nature. But really, you'll want to peruse the schedule yourself as the options are seemingly endless and you can customize your search to your interests and age range. Also, you must register (it's free!) to see full details of each event.

Events That Take You Outside

Interactive Bird Scavenger Hunt

If you've ever wanted to get into birding but find the Sibley guides overwhelming, this session is for you. Download the scavenger hunt card and join other aspiring ornithologists in observing local birds and their behavior.

Share the Night Sky

What do you get when you mix a radio show and a planetary show? This show features San Franciscos Urban Astronomer Paul Salazar and KPOO's DJ Marilynn. Tune in for a guided tour of the night sky in real time.

Events for Big Thinkers

Astronomy Talks: Quantum Mechanics vs General Relativity: Clash of the Titans

Join a discussion about unifying the two theories and creating "a single theory that describes the entire Universe." Doesn't get much bigger picture than that, now, does it?

CRISPR, Sickle Cell Disease, and Society: A VR Explainer and Ethics Discussion

Explore how CRISPR genome editing may be used to repair the sickle cell mutation. See a virtual reality tour of the human body, and a talk on health disparities in the U.S. and the ethics of CRISPR.

N ~ 1: Alone in the Milky Way

Dr. Pascal Lee, a planetary scientist who works at the Mars Institute, the SETI Institute and the Haughton-Mars Project at the NASA Ames Research Center, makes the case that "we might be it, in the vastness of our galaxy."

Events for the Foodies (or the Science-Reluctant)

The Science of Sundaes

You had me at ice cream scientist. Dr. Maya Warren will teach families how to make their own sweet treats at home and discuss her career as a "real-life ice cream scientist"!

The Science Behind Hand-Pulled Noodles

Members of the Stanford Polymer Collective will make a basic dough and explain how additives like oil, water and salt change the dough's mechanical properties. Participants are encouraged to follow along at home and decide which dough makes the best hand-pulled noodles.

Events for Climate Activists

Bay Area Youth Climate Activism Panel

Get inspired and learn from the young people in the Bay Area who are trying to save our ecosystems.

Wetland Protectors: Our First Line of Defense

Save the Bay will demonstrate why tidal marshlands and native plants are key to flood protection for bayside communities threatened by climate change.

Events at the Frontline of the Pandemic

Behind the Scenes at a COVID-19 Diagnostic Testing Center

You ever wonder what happens after the nose and throat swabs? We'll go inside a lab that's working with UCSF on COVID-19 testing. "Follow a sample from its arrival at the lab, through RNA extraction and amplification, to the end result to reveal if it is positive or negative for the virus."

Exploring Connections Between Cancer and COVID-19

Talk to researchers from the UCSF Cancer Cell Map Initiative (CCMI) and Quantitative Biology Institute Coronavirus Research Group (QBI-QCRG) about the "connections between the mechanisms of cancer and COVID-19."

Events at the Intersection of Race and Science

Cultural Tax: The Cost of Being the Only or the Few

Tyrone Poster, a principal investigator at Boston University, shares insights on the "silent burden" that often accompanies being a Black STEM student and professional.

A Conversation with the Creators of The Nocturnists

The Nocturnists is a medical storytelling community founded by two UCSF physicians. Their audio documentary series "Stories from a Pandemic" and Black Voices in Healthcare" provide unique first-person accounts from health care workers.

Events for the Creature-Curious

Catch that Critter!

Ever wonder who or what is going bump in the night in your backyard? Here's your chance! Learn how to set up a "wildlife monitoring system and hear about the critters caught on camera at the Cal State East Bay Concord Campus and cameras set up in the Diablo hills. This first event will be a how-two and the second event will give participants the chance to share what they discovered.

A Very Spine-Tingling Spider Screening with KQEDs Deep Look

Yes, this one is a shameless plug! The team behind KQED's own Deep Look video series will present three of their popular spider episodes. Deep Look producers and cinematographers will reveal how they captured the spiders behavior on camera and spider experts will be on hand to answer all your arachnid-related questions.

And there are hundreds more events on all variety of subjects: storytelling and COVID, composting, wildfires. Check out the BASF website to see them all.

Editor's Note: KQED is a media sponsor of the Bay Area Science Festival.

Follow this link:
Bay Area Science Festival 2020: From Black Holes to Sourdough, It's All Virtual - KQED

Recommendation and review posted by Bethany Smith

Indias first indigenously developed test for coronavirus disease (Covid-19) based on the genetic editing tool CRISPR/Cas-9 is likely to be available in the market by the end of October. Heres everything that you need to know about the test:

Why is the test named Feluda?

Feluda is the acronym for FNCAS9 Editor Linked Uniform Detection Assay but the test is named after a fictional private detective from West Bengal created by the renowned writer and filmmaker Satyajit Ray.

Who has developed the test?

The test was developed by a research team led by Debojyoti Chakraborty and Souvik Maiti of the Council of Scientific and Industrial Research (CSIR) and researchers from the Institute of Genomics and Integrative Biology. It will be marketed by Tata Sons and has been approved by the Drug Controller General of India last month.

What is the effectiveness of the test?

It has a sensitivity of 96 per cent and specificity of 98 per cent which means that the test can detect positive and negative cases both up to 96 or 98 per cent of the time. The test matches the accuracy levels of RT- PCR tests which are widely being used for Covid- 19 diagnosis.

How does the test work?

With quicker result time and less expensive equipment, the test uses indigenously developed CRISPR gene-editing technology. It is the worlds first diagnostic test that uses specially adapted Cas9 protein to successfully detect the virus. It requires a nasal swab to be collected and sent to a lab. The Cas9 protein is barcoded to interact with the SARS-CoV2 sequence in the patients genetic material. The Cas9-SARS-CoV2 complex is then put on the paper strip, where using two lines (one control, one test), the test determines whether the sample was infected with Covid-19.

What is the CRISPR technology?

CRISPR, short form for Clustered Regularly Interspaced Short Palindromic Repeats, is a genome editing technology used in correcting genetic defects and treating and preventing the spread of diseases. The CRISPR technology that won the Nobel Prize for chemistry this year can detect specific sequences of DNA within a gene using an enzyme functioning as molecular scissors to snip it. It also allows researchers to easily alter DNA sequences and modify gene function.

What is the cost of the test?

The Feluda test is likely to cost about Rs 500 but the final cost will only be known once the test is commercially available. In contrast, the RT-PCR test now costs anywhere between Rs 1,600 to Rs 2,000.

Read the rest here:
What is the Feluda test that will be commercially available by October 31? - Hindustan Times

Recommendation and review posted by Bethany Smith

This report also researches and evaluates the impact of Covid-19 outbreak on the CRISPR & Cas Genes industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on CRISPR & Cas Genes and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).

Global CRISPR & Cas Genes Market Overview:

The research report, titled [Global CRISPR & Cas Genes Market 2020 by Company, Regions, Type and Application, Forecast to 2025], presents a detailed analysis of the drivers and restraints impacting the overall market. Analysts have studied the key trends defining the trajectory of the market. The research report also includes an assessment of the achievements made by the players in the global CRISPR & Cas Genes market so far. It also notes the key trends in the market that are likely to be lucrative. The research report aims to provide an unbiased and a comprehensive outlook of the global CRISPR & Cas Genes market to the readers.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2696251&source=atm

Global CRISPR & Cas Genes Market: Segmentation

For clearer understanding of the global CRISPR & Cas Genes market, analysts have segmented the market. The segmentation has been done on the basis of application, technology, and users. Each segment has been further explained with the help of graphs figures. This breakdown of the market gives the readers an objective view of the global CRISPR & Cas Genes market, which is essential to make sound investments.

The major players profiled in this report include:CRISPR TherapeuticsAstraZenecaAddgeneCaribou Biosciences, Inc.CellectisEditas Medicine, Inc.EgenesisF. Hoffmann-La Roche Ltd.Horizon Discovery Group PlcGenscripDanaher CorporationIntellia Therapeutics, Inc.LonzaMerck KGaANew England BioLabsTakara Bio, Inc.

To understand the changing political scenario, analysts have regionally segmented the market. This gives an overview of the political and socio-economic status of the regions that is expected to impact the market dynamic.

Global CRISPR & Cas Genes Market: Research Methodology

To begin with, the analysis has been put together using primary and secondary research methodologies. The information has been authenticated by market expert through valuable commentary. Research analysts have also conducted exhaustive interviews with market-relevant questions to collate this research report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2696251&source=atm

Global CRISPR & Cas Genes Market: Competitive Rivalry

The research report also studied the key players operating in the global CRISPR & Cas Genes market. It has evaluated and elucidated the research and development statuses of these companies, their financial outlooks, and their expansion plans for the forecast period. In addition, the research report also includes the list of strategic initiatives that clearly explain the achievements of the companies in the recent past.

The end users/applications and product categories analysis:On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-General Type

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of CRISPR & Cas Genes for each application, including-Biomedical

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2696251&licType=S&source=atm

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global CRISPR & Cas Genes market

Chapter 2: Evaluating the leading manufacturers of the global CRISPR & Cas Genes market which consists of its revenue, sales, and price of the products

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales

Chapter 4: Presenting global CRISPR & Cas Genes market by regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

Contact Us:

marketresearchhub

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

About marketresearchhub

marketresearchhub is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfil all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organisations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

View post:
CRISPR & Cas Genes Market: Analysis and In-depth study on market Size Trends, Emerging Growth Factors and Regional Forecast to 2025 - Eurowire

Recommendation and review posted by Bethany Smith

MarketsandResearch.biz has released a recent industry research report titled Global CRISPR and Cas Genes Market 2020 by Company, Regions, Type and Application, Forecast to 2025 that spotlights on the study of past, present, and future look of the industry. The study conducted is inclusive of the industry trends and competitive and regional analysis covering the period 2020-2025. The report provides an actual industry viewpoint on market trends, dynamics for market growth rate, trading, growth rate, and revenue, in terms of demand and supply, cost structure, barriers, and challenges, product type, key market players, regions, and applications. Studying the market in terms of growth and expansion, the report covers the crucial factors influencing the global CRISPR and Cas Genes market.

Competitive Landscape:

The report analysts have identified direct or indirect market competitors, as well as comprehend their mission, vision, values, niche market, strengths, and weaknesses. The report provides Porters five forces including the threat of substitute products or services, established rivals, new entrants, and two others such as the bargaining power of suppliers and customers. Prominent players joined with their market share are highlighted in the report. The well-established players in the global CRISPR and Cas Genes market are: Synthego, OriGene Technologies, Inc., Addgene, Thermo Fisher Scientific, Inc., Transposagen Biopharmaceuticals, Inc., GenScript, Horizon Discovery Group Co., Integrated DNA Technologies, Inc., Merck, New England Biolabs, Cellecta, Inc., Agilent Technologies, Applied StemCell, Inc.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/107687

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

Geographical provincial information will help you in focusing on all the best-performing locales. The regions are extensively analyzed with respect to every parameter of the geographies in question, comprising, North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), MENA (Saudi Arabia, UAE, Turkey and South Africa)

In market segmentation by types, the report covers: Vector-based Cas, DNA-free Cas

In market segmentation by applications, the report covers the following uses: Genome Engineering, Disease Models, Others

The report evaluates production, consumption, and product segmentation highlights the current trend in the global market, and projects the revenue and potential developments of key players. Further, the report has analyzed the market concerning the regional landscape which incorporates extensive details about the types and application spectrums of this business. The research report tracks competitive growths such as joint ventures, tactical alliances, mergers and achievements, new product developments, and research and developments in the global CRISPR and Cas Genes market.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/107687/global-crispr-and-cas-genes-market-2020-by-company-regions-type-and-application-forecast-to-2025

Consumer Behavior Analysis:

Furthermore, the report analyzes the behavior of the CRISPR and Cas Genes consumers in the marketplace and looks at motives for those behavioral trends. Later, personal, and social consumer behavior is studied through focus groups, surveys, and tracking sales history. Our consumer behavior study helps businesses to understand consumers value. Not all consumers value the same benefits, so its important for businesses to segment their consumer base. Using the latest technology and analysis on the demand-side, key players are getting into consumer behavior and their changing preferences.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

Read more:
Global CRISPR and Cas Genes Market 2020 Trending Technologies, Developments, Key Players and End-use Industry to 2025 - Illadel Graff Supply

Recommendation and review posted by Bethany Smith

Stem Cell Assay Market: Snapshot

Stem cell assay refers to the procedure of measuring the potency of antineoplastic drugs, on the basis of their capability of retarding the growth of human tumor cells. The assay consists of qualitative or quantitative analysis or testing of affected tissues andtumors, wherein their toxicity, impurity, and other aspects are studied.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=40

With the growing number of successfulstem cell therapytreatment cases, the global market for stem cell assays will gain substantial momentum. A number of research and development projects are lending a hand to the growth of the market. For instance, the University of Washingtons Institute for Stem Cell and Regenerative Medicine (ISCRM) has attempted to manipulate stem cells to heal eye, kidney, and heart injuries. A number of diseases such as Alzheimers, spinal cord injury, Parkinsons, diabetes, stroke, retinal disease, cancer, rheumatoid arthritis, and neurological diseases can be successfully treated via stem cell therapy. Therefore, stem cell assays will exhibit growing demand.

Another key development in the stem cell assay market is the development of innovative stem cell therapies. In April 2017, for instance, the first participant in an innovative clinical trial at the University of Wisconsin School of Medicine and Public Health was successfully treated with stem cell therapy. CardiAMP, the investigational therapy, has been designed to direct a large dose of the patients own bone-marrow cells to the point of cardiac injury, stimulating the natural healing response of the body.

Newer areas of application in medicine are being explored constantly. Consequently, stem cell assays are likely to play a key role in the formulation of treatments of a number of diseases.

Global Stem Cell Assay Market: Overview

The increasing investment in research and development of novel therapeutics owing to the rising incidence of chronic diseases has led to immense growth in the global stem cell assay market. In the next couple of years, the market is expected to spawn into a multi-billion dollar industry as healthcare sector and governments around the world increase their research spending.

The report analyzes the prevalent opportunities for the markets growth and those that companies should capitalize in the near future to strengthen their position in the market. It presents insights into the growth drivers and lists down the major restraints. Additionally, the report gauges the effect of Porters five forces on the overall stem cell assay market.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=40<ype=S

Global Stem Cell Assay Market: Key Market Segments

For the purpose of the study, the report segments the global stem cell assay market based on various parameters. For instance, in terms of assay type, the market can be segmented into isolation and purification, viability, cell identification, differentiation, proliferation, apoptosis, and function. By kit, the market can be bifurcated into human embryonic stem cell kits and adult stem cell kits. Based on instruments, flow cytometer, cell imaging systems, automated cell counter, and micro electrode arrays could be the key market segments.

In terms of application, the market can be segmented into drug discovery and development, clinical research, and regenerative medicine and therapy. The growth witnessed across the aforementioned application segments will be influenced by the increasing incidence of chronic ailments which will translate into the rising demand for regenerative medicines. Finally, based on end users, research institutes and industry research constitute the key market segments.

The report includes a detailed assessment of the various factors influencing the markets expansion across its key segments. The ones holding the most lucrative prospects are analyzed, and the factors restraining its trajectory across key segments are also discussed at length.

Global Stem Cell Assay Market: Regional Analysis

Regionally, the market is expected to witness heightened demand in the developed countries across Europe and North America. The increasing incidence of chronic ailments and the subsequently expanding patient population are the chief drivers of the stem cell assay market in North America. Besides this, the market is also expected to witness lucrative opportunities in Asia Pacific and Rest of the World.

Global Stem Cell Assay Market: Vendor Landscape

A major inclusion in the report is the detailed assessment of the markets vendor landscape. For the purpose of the study the report therefore profiles some of the leading players having influence on the overall market dynamics. It also conducts SWOT analysis to study the strengths and weaknesses of the companies profiled and identify threats and opportunities that these enterprises are forecast to witness over the course of the reports forecast period.

Some of the most prominent enterprises operating in the global stem cell assay market are Bio-Rad Laboratories, Inc (U.S.), Thermo Fisher Scientific Inc. (U.S.), GE Healthcare (U.K.), Hemogenix Inc. (U.S.), Promega Corporation (U.S.), Bio-Techne Corporation (U.S.), Merck KGaA (Germany), STEMCELL Technologies Inc. (CA), Cell Biolabs, Inc. (U.S.), and Cellular Dynamics International, Inc. (U.S.).

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=40

About Us:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Link:
Stem Cell Assay Market In-Depth Analysis & Forecast 2017-2025 - The Think Curiouser

Recommendation and review posted by Bethany Smith

Five Indian American researchers and one Bangladeshi-American have been named among the 2020 Directors New Innovator Award recipients by the National Institutes of Health.

Among the recipients are Anindita Basu, Subhamoy Dasgupta, Deeptankar DeMazumder, Siddhartha Jaiswal, Shruti Naik, and Mekhail Anwar, according to the NIH website.

Basu, of the University of Chicago, was selected for the project, Profiling Transcriptional Heterogeneity in Microbial Cells at Single Cell Resolution and High-Throughput Using Droplet Microfluidics.

The Indian American is an assistant professor in genetic medicine at the University of Chicago and leads a multi-disciplinary research group that uses genomics, microfluidics, imaging and nano/bio-materials to develop new tools to aid in diagnosis and treatment of disease.

Basu obtained a B.S. in physics and computer engineering at the University of Arkansas, Ph.D. in soft matter physics at University of Pennsylvania, followed by post-doctoral studies in applied physics, molecular biology and bioinformatics at Harvard University and Broad Institute.

Her lab applies high-throughput single-cell and single-nucleus RNA-seq to map cell types and their function in different organs and organisms, using Drop-seq and DroNc-seq that Basu co-invented during her post-doctoral work.

Dasgupta is with the Roswell Park Comprehensive Cancer Center and was named for his project, Decoding the Nuclear Metabolic Processes Regulating Gene Transcription.

Dasgupta is an assistant professor in the Department of Cell Stress Biology at Roswell Park Comprehensive Cancer Center. He earned his B.S. from Bangalore University and M.S. in biochemistry from Banaras Hindu University, India before receiving his Ph.D. in biomedical sciences from University of North Texas Health Science Center at Fort Worth, where, as a Department of Defense predoctoral fellow, he characterized the functions of a novel gene MIEN1 in tumor progression and metastasis.

He then joined the laboratory of Bert W. O'Malley, M.D. at Baylor College of Medicine, where he studied the functions of transcriptional coregulators in tumor cell adaptation and survival, as a Susan G. Komen postdoctoral fellow.

DeMazumder, of the University of Cincinnati College of Medicine, was chosen for the project, Eavesdropping on Heart-Brain Conversations During Sleep for Early Detection and Prevention of Fatal Cardiovascular Disease.

DeMazumder joined the University of Cincinnati in 2017 as assistant professor of medicine, director of the Artificial Intelligence Center of Excellence and a Clinical Cardiac Electrophysiologist after completing his doctorate at SUNY Stony Brook in Synaptic Electrophysiology, a medical degree at Medical College of Virginia-Virginia Commonwealth University, internship at Mount Sinai and residency at University of Virginia in Internal Medicine, and clinical and research fellowships at Johns Hopkins University.

His longstanding goals are to transform clinical observations into testable research hypotheses, translate basic research findings into medical advances, and evaluate personalized treatment protocols in rigorous clinical trials, while caring for patients with heart rhythm disorders and improving their quality of life.

Jaiswal, of Stanford University, was named for his project, Clonal Hematopoiesis in Human Aging and Disease.

Jaiswal is an investigator at Stanford University in the Department of Pathology, where his lab focuses on understanding the biology of the aging hematopoietic system.

As a post-doctoral fellow, he identified a common, pre-malignant state for blood cancers by reanalysis of large sequencing datasets.

This condition, termed "clonal hematopoiesis, is characterized by the presence of stem cell clones harboring certain somatic mutations, primarily in genes involved in epigenetic regulation of hematopoiesis.

Clonal hematopoiesis is prevalent in the aging population and increases the risk of not only blood cancer, but also cardiovascular disease and overall mortality. Understanding the biology of these mutations and how they contribute to the development of cancer and other age-related diseases is the current focus of work in the lab.

Naik, of New York University School of Medicine, was named for her project, Decoding Microbe-Epithelial Stem Cell Interactions in Health and Disease.

Naik is an assistant professor at New York University School of Medicine. She received her doctorate in Immunology from the University of Pennsylvania-National Institutes of Health Graduate Partnership Program.

There she discovered that normal bacteria living on our skin, known as the commensal microbiota, educate the immune system and help protect us from harmful pathogens.

As a Damon Runyon Fellow at the Rockefeller University, Naik found that epithelial stem cells can harbor a memory of inflammation which boosts their regenerative abilities and established a new paradigm in inflammatory memory, her bio states.

The Naik lab studies the dynamic interactions between immune cells, epithelial stem cells, and microbes with a focus on 3 major areas of research: Tissue regeneration and cancer, host-microbe interactions, and early in life immunity.

Anwar, of U.C. San Francisco, was named for his project, Implantable Nanophotonic Sensors forIn VivoImmunoresponse.

Anwar, whose father is from Bangladesh, is a physician-scientist at UCSF, where he is an associate professor in the Department of Radiation Oncology. Driven by the challenges his patients face when fighting cancer specifically addressing the vast heterogeneity in treatment response by identifying the optimal treatment to pair with each patients unique biology he leads a laboratory focused on developing integrated circuits (or computer chips) forin vivocancer sensing.

After completing his bachelors in physics at U.C. Berkeley, where he was awarded the University Medal, he received his medical degree at UCSF, and doctorate in electrical engineering and computer science from the Massachusetts Institute of Technology where his research focused on using micro-fabricated devices for biological detection.

Read more from the original source:
Five Indian American Researchers Named Among NIH 2020 New Innovator Awardees - India West

Recommendation and review posted by Bethany Smith

An absolute insights and know-how of the greatest market opportunities into the relevant markets or industry required for successful business growth can be accomplished only with the best market research report. The Exosome Therapeutic Market business report provides market potential for each geographical region based on the growth rate, macroeconomic parameters, consumer buying patterns, their preferences for particular product and market demand & supply scenarios. All the studies performed to generate this industry report are based on large group sizes and also at global level. This Exosome Therapeutic Market research report provides clients with the supreme level of market data and information which is specific to their niche and their business requirements.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&rp

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

The major players covered in theExosome Therapeutic Marketreport areevox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global.Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&rp

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells are dominating in the market because mesenchymal stem cells (MSCs) are self-renewable, multipotent, easily manageable and customarily stretchy in vitro with exceptional genomic stability. Mesenchymal stem cells have a high capacity for genetic manipulation in vitro and also have good potential to produce. It is widely used in treatment of inflammatory and degenerative disease offspring cells encompassing the transgene after transplantation.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because chemotherapy is basically used in treatment of cancer which is major public health issues. The multidrug resistance (MDR) proteins and various tumors associated exosomes such as miRNA and IncRNA are include in in chemotherapy associated resistance.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system.

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology segment is dominating in the market due to rising incidence of various cancers such as lung cancer, breast cancer, leukemia, skin cancer, lymphoma. As per the National Cancer Institute, in 2018 around 1,735,350 new cases of cancer was diagnosed in the U.S. As per the American Cancer Society Inc in 2019 approximately 268,600 new cases of breast cancer diagnosed in the U.S.

Based on route of administration, the market is segmented into oral and parenteral. Parenteral route is dominating in the market because it provides low drug concentration, free from first fast metabolism, low toxicity as compared to oral route as well as it is suitable in unconscious patients, complicated to swallow drug etc.

The exosome therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes. Hospitals are dominating in the market because hospitals provide better treatment facilities and skilled staff as well as treatment available at affordable cost in government hospitals.

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Customization Available:Global Exosome Therapeutic Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&rp

About Data Bridge Market Research :

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

Go here to see the original:
Exosome Therapeutic Market 2020-2026 to Witness Excellent Growth || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH,...

Recommendation and review posted by Bethany Smith

Governor Gavin Newsom of California vetoed a bill that would have created new limitations on data sharing for direct-to-consumer genetic testing companies.

The Genetic Information Privacy Act (GIPA) asked testing companies to get informed consent from customers before disclosing their data to third parties. GIPA was aimed as a stop-gap to cover data sharing that is not already regulated by the California Consumer Privacy Act (CCPA) and the federal Health Insurance Portability and Accountability Act (HIPAA).

The final bill gained significant traction in the legislature. It passed both houses without a single vote against it.

In his veto message, the Governor expressed concern about the unintended consequences of the bill. Governor Newsom fears the bill would constrain mandatory reporting of COVID-19 test results to local public health departments and the California Department of Public Health.

California has been exceedingly active in the past few years putting forward innovative regulation of personal information. This veto is an example of the state taking a measured approach to the regulation of health data in the midst of the COVID-19 pandemic.

The Governor signaled that he supports the overall goals of the bill. He directed California state agencies to work with the Legislature on a revised version that takes into account the need to share COVID-19 testing data with authorities.

Putting it Into Practice. This version of the GIPA is put to rest. However, California has signaled it plans to pass a law regulating data sharing for genetic testing companies in the near future. Companies innovating in this area can begin reviewing their existing disclosures and consents with an eye toward getting opt-in consent in the future.

Read the rest here:
California Governor Pulls the Plug on Genetic Information Privacy Act - JD Supra

Recommendation and review posted by Bethany Smith

DETROIT (PRWEB) October 19, 2020

While most cancers happen by chance due to a variety of factors, about 10% of the time, cancer is linked to a single change in a gene, or mutation, that has been passed down from family members. This is referred to as hereditary cancer. A person who has inherited a gene mutation associated with hereditary cancer will not necessarily get cancer, but he or she is at a higher risk than those without a gene mutation. People with a mutation in either the BRCA1 or BRCA2 gene have risks of up to 87% for developing breast cancer and up to 44% for developing ovarian cancer by age 70. Womens Excellence is pleased to offer hereditary cancer testing (genetic testing) to help women identify gene mutations that may lead to certain cancers.

Dr. Jonathan Zaidan, MD, FACOG, President of Womens Excellence makes preventative care a top priority for patients at Womens Excellence.

Weve all heard the saying 'Knowledge is Power,' and that is exactly the mantra behind hereditary cancer testing, says Zaidan. Depending on your results, hereditary cancer testing provides us the information we need to create a proactive plan of care. For example, if a patient is positive for certain gene mutations, we may be able to overcome insurance barriers to allow for screening at a much earlier age. This quick and efficient tool can help save lives, and were proud to offer this advanced service at Womens Excellence!

Hereditary cancer testing (genetic testing) is a simple in-office blood test that is analyzed by a specialized laboratory.

To be eligible for genetic testing, patients need to identify their hereditary cancer risk. Womens Excellence offers a quick risk assessment survey at https://www.womensexcellence.com/risk-assessment/. Once the assessment has been completed, Womens Excellence will contact you within 72 hours to notify you on your eligibility for genetic testing.

About Womens ExcellenceWomens Excellence is the most comprehensive obstetric and gynecologic office in Michigan. Additionally, they specialize in menopause, weight control, bladder control, endometriosis, robotic surgery, oncology, and midwifery services. Womens Excellence is committed to staying at the forefront of innovation with cutting edge technologies utilizing robotic surgery and minimally invasive surgical options when possible. The knowledgeable, compassionate physicians and healthcare providers of Womens Excellence focus on patient-centered processes to deliver the highest quality of care. They are affiliated with most insurances. They offer seamless medical record access via a state-of-the-art patient portal and use the latest technology for record keeping and sharing, making the patient experience easier and more efficient. Womens Excellence is taking new patients and is conveniently located throughout southeastern Michigan in Clarkston, Lake Orion, Lapeer, Rochester, Royal Oak, and West Bloomfield. Womens Excellence is also a proud partner of Detroits longstanding radio network, WJR 760AM, providing expert womens health news and information. For more information, visit http://www.WomensExcellence.com.

Share article on social media or email:

Visit link:
Women's Excellence Offers Comprehensive Hereditary Cancer Testing in Recognition of Breast Cancer Awareness Month - PR Web

Recommendation and review posted by Bethany Smith

The globalBreast Cancer Predictive Genetic TestingMarket report offers a complete overview of the Breast Cancer Predictive Genetic Testing Market globally. It presents real data and statistics on the inclinations and improvements in global Breast Cancer Predictive Genetic Testing Markets. It also highlights manufacturing, abilities & technologies, and unstable structure of the market. The global Breast Cancer Predictive Genetic Testing Market report elaborates the crucial data along with all important insights related to the current market status.The report also presents the historic, current and expected future market size, position, of the Breast Cancer Predictive Genetic Testing industry.The report further signifies the upcoming challenges, restraints and unique opportunities in the Breast Cancer Predictive Genetic Testing market. The report demonstrates the trends and technological advancement ongoing in the Breast Cancer Predictive Genetic Testing industry. In addition to the current inclinations over technologies and capabilities, the report also presents the variable structure of the market, worldwide. The study then describes the drivers and restraints for the market along with the impact they have on the demand over the forecast period. The report also highlights technological advancements and product developments that drive market needs. The report contains a detailed analysis of the major players in the market, as well as their business overview, expansion plans and strategies. Key players explored in the report include: CompanyRoche, Thermo Fisher Scientific, PerkinElmer, Quest Diagnostics, Myriad Genetics, Iverson Genetics, Cancer Genetics, OncoCyte Corporation, NeoGenomics, Invitae

Get a Breast Cancer Predictive Genetic Testing Market Report Sample Copy @https://www.industryandresearch.com/report/Global-Breast-Cancer-Predictive-Genetic-Testing-Market-Report-Insight-Key-Research-Findings-Competative-Landscape-and-Forecast-2020-2025/201488#samplereport

The report has been curated after observing and studying various factors that determine regional growth such as economic,environmental, social,technological, and political status of the particular region. Analysts have studied the data of revenue, production,and manufacturers of each region.this section analyses region-wise revenue and volume for the forecast period of 2020 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region. The information presented in this report provides an overview of the latest trends and development plans, patterns, and policies observed in the global market. Moreover, the study provides an analysis of the latest events such as the technological advancements and the product launches and their consequences on the global Breast Cancer Predictive Genetic Testing market. Then it provides an overall competitive scenario of the market along with an advance approach to the market growth. The market is segmented by application with historical and projected market share and compounded annual growth rate. The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The fundamental purpose of Breast Cancer Predictive Genetic Testing Market report is to provide a correct and strategic analysis of the industry. The report scrutinizes each segment and sub-segments presents before you a 360-degree view of the said market.

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market.The Global Breast Cancer Predictive Genetic Testing Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts,inputs from industry experts and industry participants across the value chain. The report also maps the qualitative impact of various market factors on market segments and geographies. The report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Breast Cancer Predictive Genetic Testing market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Breast Cancer Predictive Genetic Testing market. The report provides comprehensive analysis in an organized manner in the form of tables, graphs, charts, pictures and diagrams. Organized data paves the way for research and exploration of current and future market outlooks. Additionally, an expert team of researchers talks about key drivers and restraints that are influencing on the global market growth. Additionally, it offers detailed elaboration on risks, threats, and challenges faced by industries as well as various stakeholders.

Additionally, the report provides an extensive analysis of the key geographical regions of the industry. The regional analysis covers North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. The report offers insightful information like production and consumption ratio, demand and supply, import and export ratio, and demand trends in each region. The report also covers a country-wise analysis of the segments and sub-segments of the market.

Market segment by Type, the product can be split into:High Penetrant Genes, Intermediate Penetrant Genes, Low Penetrant Genes

Market segment by Application, split into:Hospitals, Clinics, Others

Reason to buy:* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects.* The report assists in realigning the business strategies by accentuate the Breast Cancer Predictive Genetic Testing business priorities.* The report throws light on the segment expected to dominate the Breast Cancer Predictive Genetic Testing industry and market.* Forecasts the regions expected to perceive ascension.* Researchers throw light on the dynamics of the market such as drivers, restraints, trends, and opportunities.* It offers the regional analysis of the Global Breast Cancer Predictive Genetic Testing Market along with the business profiles of several stakeholders.* The newest developments within the Breast Cancer Predictive Genetic Testing industry and details of the industry leaders along side their market share and methods.* Saves time on the entry level research as the report contains principal data concerning about growth, size, leading players and segments of the industry.* Save and cut time carrying out entry-level research by characterizing the growth, size, leading players and segments within the global Market.* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players.

Read Detailed Index report @https://www.industryandresearch.com/report/Global-Breast-Cancer-Predictive-Genetic-Testing-Market-Report-Insight-Key-Research-Findings-Competative-Landscape-and-Forecast-2020-2025/201488

The Breast Cancer Predictive Genetic Testing market factors described in this report are:Key Strategic Developments in Breast Cancer Predictive Genetic Testing market:The research includes the key strategic developments of the market, comprising R&D, M&A, agreements, new product launch, collaborations, partnerships, joint ventures, and regional growth of the key competitors functioning in the market on a global and regional scale.

Key Market Features in Breast Cancer Predictive Genetic Testing Market:The report assessed key market features, including revenue, capacity, price, capacity utilization rate, production rate, gross, production, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition to that, the study provides a comprehensive analysis of the key market factors and their latest trends, along with relevant market segments and sub-segments.

Analytical Tools:The Global Breast Cancer Predictive Genetic Testing Market report provides the rigorously studied and evaluated data of the top industry players and their scope in the market by means of several analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, SWOT analysis, and ROI analysis have been practiced reviewing the growth of the key players operating in the market.

The reports conclusion reveals the overall scope of the Global Breast Cancer Predictive Genetic Testing Market in terms of feasibility of investments in the various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the market in the near future. The Global Breast Cancer Predictive Genetic Testing Market is studied on the basis of pricing, dynamics of demand and supply, total volume produced, and the revenue generated by the products. The manufacturing is studied with regards to various contributors such as manufacturing plant distribution, industry production capacity, R & D. It also provides market evaluations including SWOT analysis, investments, return analysis, and growth, trend analysis. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors, customers, research findings & conclusion, appendix & data source and Porters Five Forces Analysis.

In conclusion, the Breast Cancer Predictive Genetic Testing Market report is your trusted source for accessing research data that is expected to exponentially accelerate your business. This report provides information such as economic scenarios, benefits, limitations, trends, market growth rates, and figures. The SWOT analysis is also incorporated into the report along with the guess attainability survey and venture revenue survey.

Request customize:-If you wish to find more details of the report or want a Customization Please contacts us. You can get a detailed of the entire research here.

Contact Us @sales@industryandresearch.com

See the original post here:
Breast Cancer Predictive Genetic Testing Market Industry Development, Growth Opportunities and Demand Analysis : Roche, Thermo Fisher Scientific -...

Recommendation and review posted by Bethany Smith

Findings from the National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) support the feasibility and efficiency of using next-generation sequencing (NGS) to triage patients to investigational therapy, provided that a sufficiently large pool of agents is made available.1

Importantly, this is the largest data set ever compiled on patients with tumors that have progressed on 1 or more standard treatments, or with rare cancers for which there is no standard treatment.

Our exhaustive efforts to enlist all of the promising agents in NCI-MATCH established a new benchmark for the utility of next-generation sequencing in the conduct of clinical trials, lead author Keith T. Flaherty, MD, a medical oncologist at Massachusetts General Hospital Cancer Center in Boston, said in a press release.2 With time, the efficiency of using tumor genetic testing for broad-based clinical investigation will only increase.

In this study published in the Journal of Clinical Oncology, tumor biopsy specimens from 5954 patients with refractory malignancies at 1117 accrual sites were centrally analyzed using NGS and selected immunohistochemistry in a master screening protocol. Notably, researchers only evaluated treatments which had demonstrated clear evidence of clinical benefit or at least promising preliminary efficacy in the proposed eligibility genotype in any tumor histology.

Overall, molecular profiling was found to be successful in 93.0% of specimens. Moreover, an actionable alteration was detected in 37.6%.

Following the application of clinical and molecular exclusion criteria, 17.8% of specimens were assigned, though 26.4% could have been assigned if all subprotocols had been available simultaneously. As of the study publication, 11 subprotocols had reached their accrual goal.

Notably though, actionability rates differed among histologies; for instance, the actionability rate for urothelial cancers was 35%, while for pancreatic and small-cell lung cancer the actionability rate was 6%. Additionally, multiple actionable or resistance-conferring tumor mutations were seen in 11.9% and 71.3% of specimens, respectively.

According to researchers, these rates may increase as more drugs become available, especially those that target common gene defects.

The 6000-patient analysis from NCI-MATCH describes the genetic complexity that is characteristic of relapsed, refractory cancers, Peter J. ODwyer, MD, a medical oncologist at the University of Pennsylvania and group co-chair of the ECOG-ACRIN Cancer Research Group, said in the release. This publication represents an important milestone in the oncology fields efforts to translate a genetic understanding of cancer into improved treatments.

NCI-MATCH researchers also compared the tumor gene make-up of patients with 7 cancer types against The Cancer Genome Atlas (TCGA), including breast, bile duct, cervical, colorectal, lung, pancreatic, and prostate cancer. Ultimately, there were not many differences observed between the primary and metastatic databases. Known resistance mutations to targeted therapies were found to be numerically more frequent in NCI-MATCH than TCGA tumors, though not markedly so.

In order to better understand the differences in tumor gene make-up between primary and metastatic tumors, the investigators plan to compare the NCI-MATCH patients primary and metastatic tumors moving forward. Multiple treatment arms have also been opened in NCI-MATCH, with 38 arms of research currently ongoing.

NCI-MATCH is a unique and ground-breaking trial that will continue to make major contributions in years to come as genomic findings from individual treatment arms, correlated with outcomes, are released, Lyndsay Harris, MD, translational co-chair of NCI-MATCH and associate director of the Cancer Diagnosis Program and the Division of Cancer Treatment and Diagnosis at the NCI, said in the release.

References:

1. Flaherty KT, Gray RJ, Chen AP, et al. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). Journal of the National Cancer Institute. doi: 10.1200/JCO.19.03010

2. Genomic study of 6000 NCI-MATCH cancer patients leads to new clinical trial benchmarks [news release]. Philadelphia. Published October 13, 2020. Accessed October 14, 2020. https://ecog-acrin.org/news-and-info/press-releases/genomic-study-of-6000-nci-match-cancer-patients-leads-to-new-clinical-trial-benchmarks

Excerpt from:
NCI-MATCH Supports Using NGS to Triage Patients to Investigational Therapy - Cancer Network

Recommendation and review posted by Bethany Smith

Scientists have said that a standard gene testing for patients who have been diagnosed with metastatic gastrointestinal stromal tumors (GIST) will be more cost-effective. They have said that the financial estimate will support the widespread adoption of this approach. A study of genetic tests and modified first-line cure shows that using genetic testing to match the treatment of KIT differences to the imatinib dose is a less expensive way as compared to empirical imatinib. Experts have said that genetic test helps doctors to give chemotherapy in a tumor-specific way. In this case, those patients who do not get any relief from imatinib are given the alternative cure. This study has been published in JAMA Network Open.

The author of the study, David Geffen has said that genetic test is cheap as it avoids futile treatment and low rates of disease growth. He has made a Markov model to match the efficiency of the targeted gene test and modified first-line therapy with imatinib therapy in patients with GIST. The key factor for assessing the cost efficiency of the gene test has been quality of life years (QALY). The cost-efficiency of gene testing is defined by the incremental cost-effectiveness ratio. An incremental cost-effectiveness ratio, which is less than $100000, is considered cost-effective. As per the study, a therapy directed by the gene test is linked with an increase of 0.10 QALYs, at $9513 as compared to empirical imatinib. It leads to an incremental cost-effectiveness ratio of $92100. However, experts have said that the findings are sensitive to the costs of targeted gene tests, drugs, and health utility model efforts.

Experts have said that 70 percent of times, a targeted gene test is quite cost-efficient. The results of the study show that therapy directed by targeted gene tests can be cheaper if it gets hold of more share in the market, as of now imatinib therapy has a larger market share. Experts have advised patients with newly detected GIST that they should go for genetic testing before the start of first-line chemotherapy. They have said that this way patients who do not get any relief from imatinib, can be given a better treatment for their lumps. Experts have said that there is a need for further studies to substantiate the findings.

See the article here:
Experts Say Standard Genetic Testing Might Be Cost Effective For Newly Diagnosed Patients With GIST - Chemical Market Reports

Recommendation and review posted by Bethany Smith

The Global Direct-to-consumer Genetic Testing Market analysis report published on IndustryGrowthInsights.com is a detailed study of market size, share and dynamics covered in XX pages and is an illustrative sample demonstrating market trends. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It covers the entire market with an in-depth study on revenue growth and profitability. The report also delivers on key players along with strategic standpoint pertaining to price and promotion.

Get FREE Exclusive PDF Sample Copy of This Report: https://industrygrowthinsights.com/request-sample/?reportId=168398

The Global Direct-to-consumer Genetic Testing Market report entails a comprehensive database on future market estimation based on historical data analysis. It enables the clients with quantified data for current market perusal. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and regional analysis. Listed out are key players, major collaborations, merger & acquisitions along with upcoming and trending innovation. Business policies are reviewed from the techno-commercial perspective demonstrating better results. The report contains granular information & analysis pertaining to the Global Direct-to-consumer Genetic Testing Market size, share, growth, trends, segment and forecasts from 2020-2026.

With an all-round approach for data accumulation, the market scenarios comprise major players, cost and pricing operating in the specific geography/ies. Statistical surveying used are SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics. Graphs are clearly used to support the data format for clear understanding of facts and figures.

Customize Report and Inquiry for The Direct-to-consumer Genetic Testing Market Report: https://industrygrowthinsights.com/enquiry-before-buying/?reportId=168398

Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Primary research, interviews, news sources and information booths have made the report precise having valuable data. Secondary research techniques add more in clear and concise understanding with regards to placing of data in the report.

The report segments the Global Direct-to-consumer Genetic Testing Market as:Global Direct-to-consumer Genetic Testing Market Size & Share, by Regions

Global Direct-to-consumer Genetic Testing Market Size & Share, by ProductsDiagnostic ScreeningPrenatal, Newborn Screening, and Pre-Implantation DiagnosisRelationship TestingDirect-to-consumer Genetic Testin

Global Direct-to-consumer Genetic Testing Market Size & Share, ApplicationsOnlineOffline

Key Players23andMeMyHeritageLabCorpMyriad GeneticsAncestry.comQuest DiagnosticsGene By GeneDNA Diagnostics CenterInvitaeIntelliGeneticsAmbry GeneticsLiving DNAEasyDNAPathway GenomicsCentrillion TechnologyXcodeColor GenomicsAnglia DNA ServicesAfrican AncestryCanadian DNA ServicesDNA Family CheckAlpha BiolaboratoriesTest Me DNA23 MofangGenetic HealthDNA Services of AmericaShuwen Health SciencesMapmygenomeFull GenomesDirect-to-consumer Genetic Testin

Avail the Discount on this Report @ https://industrygrowthinsights.com/ask-for-discount/?reportId=168398

IndustryGrowthInsights offers attractive discounts on customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About IndustryGrowthInsights:INDUSTRYGROWTHINSIGHTS has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario, CA 91764, United States.Phone No: USA: +1 909 545 6473Email: [emailprotected]Website: https://IndustryGrowthInsights.com

More here:
Direct-to-consumer Genetic Testing Market | Global Industry Analysis By Trends, Size, Share, Company Overview, Growth And Forecast By 2026 - PRnews...

Recommendation and review posted by Bethany Smith